ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy
(WorldNews Belgium)

ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy The Company has passed the Last Patient Last Visit (LPLV) milestone in the pivotalgp-ASIT+TM Phase III trial and remains on track to deliver primary efficacy results in December 2019. ASIT biotech is collaborating with ICON plc (CRO) to finalize the data collection before database lock and statistical analyses. Brussels, Belgium, 26 September 2019, 07.00 am (CEST) - ASIT biotech (ASIT - BE0974289218),a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough allergy immunotherapy products, today provided an update on the phase III...